Mad, Mad Science: Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses – Where Will It All End?
TAGline • 1994Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses – Where Will It All End? When Good ‘Trapping’ Is Bad Craig Sterritt has been tracking down the latest AIDS pathogenesis research – in addition to his project researching immune-based therapies. Here’s some of what came out of the meeting in Yokohama. An increasing…
Caveat Emptor: Yokohama Roundtable Examines Treatment Quandary Facing Patients, Clinicians Alike
TAGline • 1994Yokohama Roundtable Examines Treatment Quandary Facing Patients, Clinicians Alike Burning Last Lightbulb At Noon Mark Harrington was invited to speak at the Thursday afternoon roundtable discussion in Yokohama, “When To Start Antiretroviral Treatment.” The session was moderated by Australia’s BW poster-doc, David Cooper, and WHO’s recent “it’s-never-too-early” convert, Dr. Joep Lange. Joining Mark at the…
Looking Where the Light Is: Garbage In, Garbage Out; Could It Be We’re Asking Good Questions Of Bad Systems?
TAGline • 1994Garbage In, Garbage Out; Could It Be We’re Asking Good Questions Of Bad Systems? A Case of Turncoat Tropism — Or, Living and Dying With “NSI” Why after more than a decade of AIDS research do we still know so very little about how HIV runs its devastating course through the human body? Besides the…
ACTG Rescue Plan: Tome of Recommendations Would Abolish ACDDC, Mandate Costing-Out and Establish Advisory Review Group
TAGline • 1994Tome of Recommendations Would Abolish ACDDC, Mandate Costing-Out and Establish Advisory Review Group Finding the Political Will … “The up-coming ACTG re-competition provides an opportunity to re-envision AIDS clinical research for the next 5 years. It looks likely, however, that this opportunity will be missed. Current plans call for only incremental changes. They address the…
Inter-Company Cahoots: ICC’s Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That?
TAGline • 1994ICC’s Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That? “It’s ddC Monotherapy All Over Again” A hastily organized meeting of the newly formed Inter-Company Collaborative (ICC) was convened April 26 at the Loews New York Hotel to discuss the ICC’s master protocol for triple drug combination therapy.…
Stavudine for Everyone: Accelerated Approval Guidelines Expedite Bristol’s Launch of New Nucleoside — In the Absence of Any Proof That It Works
TAGline • 1994Accelerated Approval Guidelines Expedite Bristol’s Launch of New Nucleoside — In the Absence of Any Proof That It Works Specter of Fast Track Review Haunts Those Who Spawned It “FDA Panel Recommends Drug Despite Incomplete Data.” So read the New York Times headlines emblazoned above the brief article summarizing the proceedings of the May 20th…
Pathogenesis + Activism, Speech by Mark Harrington
Publication • 1992Speech by Mark Harrington Presented at VIII International Conference on AIDS, Amsterdam, July 22, 1992 I would like to dedicate my remarks today to my colleagues in the struggle against AIDS who did not survive the year since this group last met in Florence – to Charles Barber, Daniel Sotomayor, David Byar, David Lopez, Donald…
AIDS Research at the NIH: A Critical Review Part I: Summary
Publication • 1992By Gregg Gonsalves and Mark Harrington VIII International Conference on AIDS, Amsterdam, the Netherlands, July 20, 1992 From the Introduction Since 1987, the activist critique of AIDS research has worked its way back: from drug approval at the regulatory level of the US Food + Drug Administration (FDA), to expanded access for drugs still under…